Lipid-lowering effects of zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, in high-fat diet-induced hyperlipidemic hamsters.
We investigated the effects of zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, on high-fat diet (HFD)-induced hyperlipidemic hamsters. After being fed HFD for 2 weeks, Syrian golden hamsters were dosed orally with zerumbone (25, 50, and 100 mg/kg) once daily for 8 weeks. Decreased plasma levels of TC, TG and LDL-C, as well as the concentrations of hepatic lipids, with a simultaneous increase in fecal lipids were found. The ratios of LDL-C/HDL-C and TC/HDL-C were elevated by zerumbone. Zerumbone exhibited the ability to decreased hepatic mRNA levels of fatty acid synthase, malic enzyme, sterol-regulatory element binding protein and 3-hydroxy-3-methyl-glutaryl-CoA reductase reductase. The hepatic mRNA expression of peroxisome proliferator-activated receptor α, together with its target gene carnitine palmitoyl transferase and acyl-CoA oxidase were also upregulated by zerumbone. Zerumbone is effective to improve dyslipidemia by modulating the genes expression involving in the lipolytic and lipogenic pathways of lipids metabolism.
Department of Internal Medicine, Pao Chien Hospital, Ping Tung City, Pingtung County, Taiwan, ROC.
Thing-Fong
TF
Tzeng
Traditional Medicinal Center, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, ROC.
Hung-Jen
HJ
Lu
Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Yanpu Shiang, Ping Tung Shien, Taiwan, ROC.
Shorong-Shii
SS
Liou
Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Yanpu Shiang, Ping Tung Shien, Taiwan, ROC.
Chia Ju
CJ
Chang
Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Yanpu Shiang, Ping Tung Shien, Taiwan, ROC. Electronic address: iml@tajen.edu.tw.
I-Min
IM
Liu
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002334:Carnitine O-Palmitoyltransferase / Q000235:genetics; D059305:Diet, High-Fat / Q000009:adverse effects*; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D005243:Feces; D005786:Gene Expression Regulation / Q000187:drug effects; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy*; D008049:Lipase / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects / Q000235:genetics; D008055:Lipids / Q000097:blood; D008066:Lipolysis / Q000187:drug effects / Q000235:genetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D008647:Mesocricetus; D012717:Sesquiterpenes / Q000737:chemistry / Q000494:pharmacology*; D051780:Sterol Regulatory Element Binding Protein 1 / Q000235:genetics; D030521:Zingiberaceae / Q000737:chemistry*
D008055:Lipids; D012717:Sesquiterpenes; D051780:Sterol Regulatory Element Binding Protein 1; C403304:zerumbone; D002334:Carnitine O-Palmitoyltransferase; D008049:Lipase
High fat diet; Hyperlipidemic hamsters; Lipids metabolism; Zerumbone